HomeNewsIndiaCoronavirus pandemic | India and US collaborating on combating COVID-19: Ambassador Taranjit Singh Sandhu

Coronavirus pandemic | India and US collaborating on combating COVID-19: Ambassador Taranjit Singh Sandhu

The deadly coronavirus that first emerged in China's Wuhan city has drastically spread around the world, infecting 471,518 people and causing 21,293 deaths, according to the Johns Hopkins coronavirus tracker.

March 26, 2020 / 11:54 IST

India and the US are working together on combating the deadly coronavirus and collaboration is underway in the areas of diagnostics and therapeutics of the disease, which so far has taken the lives of more than 20,000 people globally, according to the Indian envoy here.

The deadly coronavirus that first emerged in China's Wuhan city has drastically spread around the world, infecting 471,518 people and causing 21,293 deaths, according to the Johns Hopkins coronavirus tracker.

"In the present context of COVID-19 pandemic, close collaboration in the areas of diagnostics and therapeutics of the disease is underway,” India's Ambassador to the US, Taranjit Singh Sandhu told PTI.

"India and the United States have had a long-standing productive partnership in the healthcare sector, especially between the research institutions and industries of both countries,” he said.

Under the existing bilateral collaboration in healthcare sector- the National Institute of Allergy and Infectious Disease in the US shared the important reagents with the Translational Health Science Technology Institute in Gurgaon.

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show

Such cooperation is expected to play a big role in developing new therapeutics and testing reagents for the COVID-19.

In addition, India-based vendors of American companies are in touch with the Indian Council of Medical Research to engage and enhance the capabilities for COVID-19 test in India.

"The US will work shoulder to shoulder with India to combat the COVID19 outbreak. Together, we can safeguard our citizens and people everywhere," Acting Assistant Secretary of State for South and Central Asia, Alice G Wells, said in a tweet referring to the cooperation between the two countries.

The United States, she said, stands united with India and echoes Prime Minister Narendra Modi's call to keep up their fighting spirits.

Cooperation and collaboration in the sector of coronavirus was also discussed between the two countries when President Donald Trump met Prime Minister Modi in New Delhi last month.

Trump and Modi also hailed a bilateral Memorandum of Understanding (MOU) that seeks to promote access to high quality, safe, effective, and affordable medications for US and Indian consumers.

In 2012, the Center for Disease Control collaborated with National Centre for Disease Control to establish Epidemic Intelligence Service (EIS) Programme.

This post-graduate field-training programme, modelled after the CDC's Epidemic Intelligence Service (EIS), has expanded to two additional hubs at the WHO India Country Office and at the India Council of Medical Research (ICMR) and the National Institute of Epidemiology.

According to the CDC, it has helped strengthen national surveillance for detecting and responding to healthcare associated infections and emerging antimicrobial resistance threats in health facilities in 22 states.

A public-private partnership helped increase capacity to diagnose, treat, and care for multidrug-resistant TB (MDR-TB) patients through virtual platforms. In Mumbai, the CDC helped the municipality and local partners, launch an Airborne Infection Control Unit to reduce healthcare-associated transmission of MDR-TB.

The CDC has helped India in implementing a surveillance system in 35 hospitals and 22 states for healthcare associated infections. It has evaluated 346 laboratory facilities across the country to identify needs and trained more than 1,700 laboratorians on quality diagnostic testing/reporting of priority diseases.

PTI
first published: Mar 26, 2020 11:35 am

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Subscribe to Tech Newsletters

  • On Saturdays

    Find the best of Al News in one place, specially curated for you every weekend.

  • Daily-Weekdays

    Stay on top of the latest tech trends and biggest startup news.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347